Researcher Traces Complex Path From Theory to Treatment
Publication: Psychiatric News
Finding new treatments for disease begins and ends with the patient, with significant steps in between, said David Lewis, M.D., in a lecture at APA's 2001 annual meeting in Honolulu in May.
David Lewis, M.D.: "A translational neuroscience approach to understanding disease processes in schizophrenia could lead us from dependence on serendipity to a rational basis for novel, effective treatments."
Credit: David Hathcox
The initial clinical observations of the patient must be converted into hypotheses about the disease processes. These can then be tested under controlled conditions in the lab to guide novel treatments for patients, said Lewis, professor and chair of the Department of Psychiatry at the University of Pittsburgh and medical director and director of research at the Western Psychiatric Institute and Clinic.
"To make that work requires a molecular target within the pathological entity that can be affected by a drug," he said. There must also be a biomarker to measure the function of the brain in a living human being. Finally, behavioral changes in the clinical syndrome must be measurable, too.
Lewis uses that approach while focusing on cognitive deficits that are core symptoms in schizophrenia—attention, executive function, and memory.
These are also among the early warning signs of the disorder, said Lewis. Young people who go on to develop schizophrenia score 1.5 to 2 standard deviations below the general population on measures of cognition as early as age 7.
Those cognitive deficits persist across the course of illness, predict long-term functional outcomes, and are often present in milder forms in relatives of people with schizophrenia.
Working memory is particularly impaired in patients with schizophrenia, said Lewis. His search for a hypothesis began with knowledge that GABA activity is needed for the proper working of the dorsolateral prefrontal cortex during working memory tasks. GABA neurons control the timing of activities there and GABA antagonists there disrupt working memory.
"You need the right amount of GABA at the right time for normal working memory," he said.
A form of glutamic acid decarboxylase (GAD67) converts GABA into glutamate. Neurons in people with schizophrenia show an average of 15 percent lower expression of GAD67 mRNA, compared with controls, although with much variance, said Lewis.
"But, are the lower GAD67 mRNA levels a reflection of the disease process or a consequence of it?," he asked.
The former, he said. "They are a conserved feature associated with the diagnosis of schizophrenia that actually affects the disease process."
With too little GAD67, there's too little GABA, he hypothesized, and that leads to a number of compensatory changes in the brain observed in schizophrenia, including a loss of gamma synchronicity, which contributes to working memory impairments.
Simply boosting GABA all the time won't affect the deficit, but selectively augmenting GABA neurotransmitters at the GABAA-alpha2 receptors while retaining the synchronicity might help the brain with compensatory responses, he suggested.
Drugs called positive allosteric modulators (such as benzodiazepines) bind to the alpha2 subunits, but they also bind to alpha1 subunits, with sedative effects, and to alpha5 subunits, impairing hippocampal memory functions.
"So we want to find a GABAA-alpha2 positive allosteric modulator to enhance GABA neurotransmission onto pyramidal cells only by way of GABAA-alpha2 receptors, which would enhance the ability for GABA neurons to entrain pyramidal cells into gamma oscillations and improve working memory," he said.
Lewis and his colleagues tested an experimental drug with those properties, MK-077, in a randomized, double-blind, controlled trial of 15 subjects. (MK-077 was originally developed as a nonsedating antianxiety drug.) They found some improvement on several cognitive tests reflecting processes in the dorsolateral prefrontal cortex, which is known to be impaired in schizophrenia.
"Enhanced signaling through these GABA receptors may improve both the biological and behavioral measures of prefrontal cortical function in people with schizophrenia," he said.
The research also suggests that targeting these receptors in people showing prodromal cognitive impairments serves as a preventive intervention.
"But this is only one pathway," he said. Others must be explored as well.
Although the trial was small and needs replication, it does suggest the approach's value to finding drug targets.
"This translational neuroscience approach to understanding disease processes in schizophrenia could lead us from dependence on serendipity to a rational basis for novel, effective treatments," he stated.
Information & Authors
Information
Published In
History
Published online: 15 July 2011
Published in print: July 15, 2011
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).